New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
07:04 EDTNNVCNanoViricides reports R&D Lab, cGMP facility near construction completion
NanoViricides reported that construction of the modern R&D Lab and cGMP Clinical Production facility in Shelton, Connecticut, is nearing completion on schedule. The company reports that the R&D lab section of the facility is nearing completion, slightly ahead of schedule. In addition, construction of the cGMP Clean Room Production Suite is expected to be completed in March, 2014, on schedule, and shortly thereafter, the project will enter facility testing and validation phase. After construction is complete, the facility, and particularly the cGMP Clean Room Suites will undergo facility testing and validation to ascertain that the facility satisfies the requirements. After validation, the company plans to occupy the new facility while keeping the current facility active to minimize impact on the multiple nanoviricides® drug development projects. The company intends to first start production of FluCide in the cGMP section, set up appropriate cGMP operation for this production, produce multiple batches of FluCide under cGMP conditions, and demonstrate equivalence of the batches produced, in preparation for human clinical trials.
News For NNVC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 11, 2016
07:08 EDTNNVCNanoViricides partners with University of Pittsburgh for drug candidate testing
Subscribe for More Information
February 1, 2016
07:12 EDTNNVCNanoViricides signs agreement with University of Wisconsin
NanoViricides announced that it has entered into an agreement with the University of Wisconsin for the evaluation of its nanoviricides drug candidates in models of ocular herpes virus infections. The studies will be performed in the laboratory of Dr. Curtis Brandt, an expert in herpes simplex virus infections and in evaluating anti-viral agents. The Company has previously reported the successes of its nanoviricides drug candidates in pre-clinical studies of dermal herpes virus infections in mouse models. The studies in Dr. Brandt's laboratory will be critical in optimizing its anti-herpes drug candidates against ocular herpes virus infections. The goal of these studies will be to identify a drug development candidate as a treatment for ocular keratitis in humans caused by herpes simplex virus infections.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use